FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis. PMID 36717798 · BMC Cancer · 2023-Jan-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. PMID 36717792 · BMC Cancer · 2023-Jan-30 The study is a bioinformatics/prognostic modeling analysis using public TCGA data, not a report of a randomized clinical trial with a drug intervention. It lacks the required Phase III/IIIb or Phase II/III evidence and a drug-containing intervention arm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol. PMID 36717150 · BMJ Open · 2023-Jan-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Advances in cancer vaccines for immunotherapy of prostate cancer. PMID 36935188 · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023-Jan-28 This is a review article, not an original report of a randomized trial. It mentions trials but does not present primary or secondary time-to-event efficacy results from a specific drug-containing intervention trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. PMID 36412114 · Jpn J Clin Oncol · 2023-Jan-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. PMID 36707808 · BMC Cancer · 2023-Jan-27 The record describes a phase IIIb, single-arm trial. While it meets criteria for oncology, human study, drug intervention, and time-to-event endpoints, the explicit 'single-arm' design fails the requirement for a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of blended and unguided online delivery of mindfulness-based cognitive therapy versus care as usual on distress among cancer patients and survivors: protocol for the three-arm parallel randomized controlled buddy trial. PMID 36698197 · BMC Psychol · 2023-Jan-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). PMID 36694252 · Trials · 2023-Jan-24 The record is a published erratum with an empty abstract. The deterministic review signals no time-to-event endpoint, no drug intervention, and cannot establish phase, human subjects, or original result status. Therefore, it does not meet the criteria for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. PMID 36771262 · Nutrients · 2023-Jan-20 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Study protocol of ConquerFear-HK: a randomised controlled trial of a metacognition-based, manualised intervention for fear of cancer recurrence among Chinese cancer survivors. PMID 36669845 · BMJ Open · 2023-Jan-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Short-term complications after onlay versus preperitoneal mesh repair of umbilical hernias: a prospective randomized double-blind trial. PMID 36662265 · Langenbecks Arch Surg · 2023-Jan-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. PMID 36649675 · J Clin Oncol · 2023-Jan-20 The record is an original final result of a randomized, controlled oncology trial with a drug intervention and primary time-to-event efficacy endpoints (RFS, OS). However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided abstract or metadata. The 'Controlled Clinical Trial' and 'Clinical Trial' publication types are insufficient to definitively confirm a Phase III/IIIb designation per the adjudication rules, which require explicit phase evidence without inference. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. PMID 35960908 · J Clin Oncol · 2023-Jan-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. PMID 36652352 · N Engl J Med · 2023-Jan-19 The trial is a well-conducted, randomized, noninferiority study comparing aspirin vs. LMWH for thromboprophylaxis in fracture patients, with 90-day mortality as the primary outcome. However, it is not an oncology trial and does not involve cancer treatment or a cancer-specific time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The mortality endpoint is a general safety/clinical outcome, not a tumor-specific efficacy endpoint with Kaplan-Meier analysis for malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. PMID 36260765 · Blood · 2023-Jan-19 This is a prospective observational study, not a randomized trial. While it is an oncology study in humans with a time-to-event endpoint (survival), it is not a randomized Phase III/IIIb or Phase II/III trial of a drug-containing intervention. The study evaluates the association of hematopoietic stem cell transplantation (a procedure) with survival, but it is not a randomized controlled trial of a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reducing tobacco-associated lung cancer risk: a study protocol for a randomized clinical trial of AB-free kava. PMID 36653872 · Trials · 2023-Jan-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. PMID 36239405 · Oncologist · 2023-Jan-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma. PMID 35881028 · Oncologist · 2023-Jan-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant treatment for stage III and IV cutaneous melanoma. PMID 36648215 · Cochrane Database Syst Rev · 2023-Jan-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Rectal stimulation with prebiotics and probiotics before ileostomy reversal: a study protocol for a randomized controlled trial. PMID 36647079 · Trials · 2023-Jan-17 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach. PMID 36760246 · Ann Transl Med · 2023-Jan-15 This is a review article (report_type: 'other') that proposes reporting guidelines based on a review of oncology trials. It is not an original clinical trial report with a drug intervention and a time-to-event efficacy endpoint. Therefore, it is ineligible. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India. PMID 36321193 · Cancer · 2023-Jan-15 The record is a randomized controlled trial evaluating a screening intervention (clinical breast examination) for breast cancer. While it is oncologic, human, and randomized, it lacks a drug-containing intervention and does not present a standard time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with a Kaplan-Meier estimate or hazard ratio. The study reports incidence rates, mortality rates (rate ratios), and survival rates, which are not the specified time-to-event endpoints. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the intervention is non-pharmacologic. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. PMID 36640225 · Funct Integr Genomics · 2023-Jan-14 The study is a prognostic/bioinformatics analysis of cuproptosis-related lncRNAs in breast cancer using TCGA data. It is randomized for data splitting (training/test), but this is not a randomized clinical trial of a therapeutic intervention. The 'drug intervention' criterion is not met because the study does not involve testing any therapeutic agent; it is purely a computational/genomic analysis for biomarker discovery. The 'phase3_or_definitive' criterion is not met as it is not a Phase III/IIIb or Phase II/III clinical trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). PMID 36631725 · Breast Cancer Res · 2023-Jan-11 This is an original report of a Phase III randomized trial in oncology with a drug intervention. However, the primary/key secondary endpoint is pathologic complete response (pCR), which is a categorical efficacy outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). The abstract describes biomarker subgroup analyses of pCR rates and does not report time-to-event data or Kaplan-Meier estimates/HRs for survival or progression-free endpoints. Therefore, it does not meet the inclusion criterion for a time-to-event primary/key secondary efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pathway Of Low Anterior Resection syndrome relief after Surgery (POLARiS) feasibility trial protocol: a multicentre, feasibility cohort study with embedded randomised control trial to compare sacral neuromodulation and transanal irrigation to optimised conservative management in the management of major low anterior resection syndrome following rectal cancer treatment. PMID 36627161 · BMJ Open · 2023-Jan-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Transanal versus laparoscopic total mesorectal excision for mid and low rectal cancer (Ta-LaTME study): multicentre, randomized, open-label trial. PMID 36224406 · Br J Surg · 2023-Jan-10 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. PMID 36223555 · J Clin Oncol · 2023-Jan-10 The record describes a randomized, controlled trial with a drug intervention (mitomycin) and a time-to-event efficacy endpoint (recurrence-free survival analyzed by Kaplan-Meier). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. The deterministic review also flagged 'phase3_evidence_unclear'. Without explicit evidence of the trial being Phase III/IIIb or Phase II/III, the record cannot be confirmed as meeting all eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). PMID 36070540 · J Clin Oncol · 2023-Jan-10 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. PMID 36049147 · J Clin Oncol · 2023-Jan-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). PMID 35944235 · J Clin Oncol · 2023-Jan-10 The record is a secondary analysis of a randomized trial (CALGB/SWOG 80702) investigating the association between physical activity and DFS. While the underlying trial is Phase III, this report is not an original report of the trial's primary efficacy results for the drug intervention (FOLFOX ± celecoxib); it is a secondary/prognostic analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. PMID 35867960 · J Clin Oncol · 2023-Jan-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A preoperative magnetic resonance imaging-based model to predict biochemical failure after radical prostatectomy. PMID 36624154 · Sci Rep · 2023-Jan-09 Study is a retrospective analysis of a diagnostic/predictive model (MRI-based) for biochemical failure after radical prostatectomy. It is randomized (for cohort split), but lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary outcome is predictive accuracy (AUC, decision curves), not a Kaplan-Meier or HR-based time-to-event analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania. PMID 36460537 · Vaccine · 2023-Jan-09 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| In vivo detection of bile duct pre-cancer with endoscopic light scattering spectroscopy. PMID 36611024 · Nat Commun · 2023-Jan-07 The record describes a diagnostic study, not a therapeutic trial. While it is randomized and involves human oncology patients, it lacks a drug intervention and a time-to-event efficacy endpoint, and the trial phase is not established as Phase III or definitive. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). PMID 36495881 · Lancet · 2023-Jan-07 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Asia-Pacific multicentre randomized trial of laparoscopic versus open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial). PMID 36849753 · BJS Open · 2023-Jan-06 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Single-stapling technique versus hand-sewn anastomosis in inter-sphincteric resection with transanal total mesorectal excision (Super SST): protocol for a multicentre randomized clinical trial. PMID 36638066 · BJS Open · 2023-Jan-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study. PMID 36609283 · BMC Urol · 2023-Jan-06 The record is a retrospective cohort study using registry data, not a prospective randomized controlled trial, and thus does not meet the required phase or trial design criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. PMID 36398439 · Jpn J Clin Oncol · 2023-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer. PMID 36151049 · Jpn J Clin Oncol · 2023-Jan-06 The record is an original result study on a human malignant neoplasm with a time-to-event endpoint, but it is a biomarker/prognostic factor study, not a drug intervention trial. The abstract describes measuring integrin alpha 2 expression in surgical samples and analyzing survival, with in vitro experiments using an inhibitor (E7820) for mechanistic validation. There is no evidence of a randomized, controlled, clinical drug intervention trial in patients. The 'Randomized Controlled Trial' publication_type is inconsistent with the abstract content. Therefore, it does not meet the core eligibility criteria of being a randomized drug intervention trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. PMID 35648151 · Inflamm Bowel Dis · 2023-Jan-05 The study reports long-term herpes zoster incidence and risk factors from Phase III clinical trials of tofacitinib in ulcerative colitis, which is not an oncology indication. While it is a human, randomized, Phase III study with a drug intervention and reports original results, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as defined in the criteria. The analysis is a safety/efficacy study of infection risk, not a Kaplan-Meier or HR analysis of tumor-related outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI. PMID 35640975 · Neuro Oncol · 2023-Jan-05 The record describes a randomized Phase III trial of HA-PCI versus conventional PCI for small cell lung cancer, which meets oncology, human, randomized, and phase criteria. However, it is ineligible because the intervention is non-drug-only (comparing radiotherapy techniques), and the primary endpoint is not a time-to-event efficacy measure (e.g., OS, PFS, DFS) but rather neuroimaging atrophy and cognitive outcomes. The deterministic review correctly identified the absence of time-to-event signal and drug intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. PMID 36318705 · Clin Cancer Res · 2023-Jan-04 This is a post-hoc, exploratory subgroup analysis focusing on the efficacy of olaparib in a specific subset of patients (Cohort A) identified via ctDNA testing. While it reports results from a Phase III randomized trial with a time-to-event endpoint (rPFS) and drug intervention, it does not represent the primary or key secondary result report for the overall trial population. Therefore, it does not meet the criterion for being an 'original formal-result report' of the trial's primary or key secondary analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. PMID 36165912 · Clin Cancer Res · 2023-Jan-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. PMID 36602796 · JAMA Netw Open · 2023-Jan-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?: A Systematic Review. PMID 37378896 · Pancreas · 2023-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Accelerated Partial Breast Irradiation: Florence Phase 3 Trial Experience and Future Perspectives. PMID 36472353 · Am J Clin Oncol · 2023-Jan-01 The record describes a Phase III randomized trial in oncology (breast cancer) but the intervention is radiation therapy (non-drug) and no time-to-event efficacy endpoint is identified in the provided abstract. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma: A Randomized Clinical Trial. PMID 36409480 · JAMA Neurol · 2023-Jan-01 The study is a randomized clinical trial on chronic subdural hematoma (neurosurgery), not a malignant neoplasm. It does not involve a drug-containing intervention (only compares irrigation fluid temperatures). The primary endpoint (recurrence requiring reoperation) is not a standard time-to-event oncology endpoint like OS, PFS, etc., and no Kaplan-Meier or HR analysis is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. PMID 36394849 · JAMA Oncol · 2023-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial. PMID 36383362 · JAMA Surg · 2023-Jan-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |